Bispecific PD1-TIM3 Antibodies
Summary
The European Patent Office published patent application EP3649155A1 for Merus B.V., covering bispecific antibodies targeting PD1 and TIM3 antigens. The patent names six inventors and designates 37 European states for protection. This is a standard patent publication providing public notice of intellectual property rights in the pharmaceutical biotechnology space.
What changed
The EPO published patent EP3649155A1 for Merus B.V. (Utrecht, Netherlands), claiming bispecific anti-PD1 and anti-TIM3 antibodies for therapeutic use. The application names inventors GEUUIJEN, KLOOSTER, DE KRUIF, TACKEN, THROSBY, and LOGTENBERG. IPC classifications indicate pharmaceutical (A61K) and protein (C07K) technology focus, with designations covering all major EU member states and extended European states.
Patent publications do not impose compliance obligations on third parties. Pharmaceutical companies and biotechnology firms developing similar bispecific antibody technologies should review the claims to assess potential freedom-to-operate implications or licensing needs. This publication does not require any regulatory action from industry participants.
Source document (simplified)
BISPECIFIC ANTI PD1-ANTI TIM3 ANTIBODIES
Publication EP3649155A1 Kind: A1 Mar 25, 2026
Applicants
Merus B.V.
Inventors
GEUIJEN, Cecilia Anna Wilhelmina, KLOOSTER, Rinse, DE KRUIF, Cornelis Adriaan, TACKEN, Paulus Johannes, THROSBY, Mark, LOGTENBERG, Ton
IPC Classifications
C07K 16/28 20060101AFI20190111BHEP A61K 39/00 20060101ALI20190111BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.